Background: Endometrial carcinoma (EC) is a common gynecological malignancy, yet the mechanisms that lead to tumor development and progression are still not fully know
Objectives: We aimed to evaluate immunohistochemical (IHC) expression of MMP14, β1 integrin and YAP1 in EC type I and its relation to clinic-pathological parameters
Subjects and Methods: IHC expression of MMP14, β1-integrin & YAP1 in 52 cases of EC type I (endometrioid type) were studied. The association of these markers with each other as well as with clinic-pathological parameters were
evaluated.
Results: Positive membranous and cytoplasmic IHC expression of MMP14 was detected in 36 (69.2%) of studied EC cases. Comparison of MMP14 IHC expression with the clinic-pathological data revealed higher expression
of MMP 14 in high grades EC (II & III) and higher stages (II& III), compared to lower grades and stages but did not reach significant difference (P=0.077, P=0.925 respectively). No significant statistical difference with other variables were detected (P>0.05 for all) Cytoplasmic localization of β1 integrin was detected in 33 (63.5%) of studied EC cases.
Significant statistical difference with grade, depth of invasion (p0.05 for all). Nuclear IHC expression
of YAP1 was detected in 34(65.4%) of studied EC cases. There was significant statistical difference with grade & depth of invasion (p=0.001 for both), mean tumor size (P=0.033), LVI (p |
